Regencell Bioscience
- Market cap
- 3.53B
- P/E (TTM)i
- -296.25
- P/Bi
- 263.33
- EPSi
- -0.02
- Div yieldi
- 0.00%
- 52W posi
- 4%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Regencell Bioscience (RGC) | 3.53B | -296.25 | 263.33 | 0.00% |
| Takeda Pharmaceutical (TAK) | 58.68B | -55.67 | 1.23 | 3.26% |
| Teva Pharmaceutical Industries (TEVA) | 45.70B | 65.30 | 5.89 | 0.00% |
| Haleon (HLN) | 39.67B | 18.87 | 1.83 | 2.11% |
| Zoetis (ZTS) | 29.57B | 11.67 | 9.39 | 2.88% |
| United Therapeutics (UTHR) | 23.38B | 19.53 | 3.65 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 67.6% below Morningstar's fair value estimate.
Fair value
Regencell Bioscience Holdings Ltd may seem undervalued at first glance, due to its considerable price decline over the past year. However, to account for the risk associated with a potential value trap, we have limited its rating to 3 stars. The stock currently trades at a 41% discount to our quantitative fair value estimate of $11.91 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.
Economic moat
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-10-08 05:07:29 · For reference only, not investment advice and not tailored to your situation.